Metrics as of 10/17/2026, 08:50 AM (Berlin time), refresh in progress.
Insight Molecular Diagnostics Stock
Insight Molecular Diagnostics Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- Joshua Riggs
- Employees
- 57
- Market cap
- $99 M
- IPO
- 30/12/2015
- Web
- imdxinc.com
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include…
Insight Molecular Diagnostics stock: price history
1D
-1.6%
1W
-10.7%
1M
-15.9%
6M
-21.6%
YTD
-59.9%
1Y
-35.0%
2Y
-3.2%
5Y
-95.6%
10Y
-96.4%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~20% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 12/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Insight Molecular Diagnostics
Analyst assessment of Insight Molecular Diagnostics
PRICE TARGET LOW
US$8.00
CONSENSUS
US$9.75
MEDIAN
US$9.50
PRICE TARGET HIGH
US$12.00
0
STRONG BUY
7
BUY
4
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 18/08/2026
Insight Molecular Diagnostics stock metrics
P/E
-1.98
P/B
-5.19
EV/EBITDA
-1.78
RETURN ON EQUITY
52.9%
NET MARGIN
-4,711.3%
DEBT/EQUITY
-0.12
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
30.5%
FLOAT SHARES
9,977,961
AVG. DAILY VOLUME (30D)
295,951
Insider transactions (SEC)
Arno Andrew
Last Andrew J.
SILVERMAN LOU
Arno Andrew
Last Andrew J.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Insight Molecular Diagnostics stock
What does Insight Molecular Diagnostics do?
Insight Molecular Diagnostics Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is Joshua Riggs, the company employs around 57 people.
The IPO was on 30/12/2015; the stock trades on NASDAQ under the ticker IMDX.
What do analysts say about Insight Molecular Diagnostics stock?
11 analysts rate the stock, the consensus is Buy (as of 18/08/2026).
The average price target is US$9.75, ranging from US$8.00 to US$12.00, with a median of US$9.50.
This is an external assessment, not a statement by Market Jury.
When does Insight Molecular Diagnostics report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 20% stronger than usual.
Does Insight Molecular Diagnostics pay a dividend?
No, Insight Molecular Diagnostics currently does not pay a dividend.
Which stocks are comparable to Insight Molecular Diagnostics?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get Insight Molecular Diagnostics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Insight Molecular Diagnostics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.